A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
Objectives Immunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-02-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748241237331 |
| _version_ | 1797271026662375424 |
|---|---|
| author | Jeremy P. Harris MD, MPhil Jino Park MD Eric Ku MD Steven Seyedin MD Russell Stitzlein MD Amanda Goldin MD Wen-Pin Chen MS Christine McLaren PhD Allen M. Chen MD Warren Chow MD |
| author_facet | Jeremy P. Harris MD, MPhil Jino Park MD Eric Ku MD Steven Seyedin MD Russell Stitzlein MD Amanda Goldin MD Wen-Pin Chen MS Christine McLaren PhD Allen M. Chen MD Warren Chow MD |
| author_sort | Jeremy P. Harris MD, MPhil |
| collection | DOAJ |
| description | Objectives Immunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the responses to immunotherapy is with stereotactic body radiation therapy (SBRT), which can enhance the antitumor CD8 T cell response through the release of tumor-specific antigens, potentially priming a more diverse class of T cell receptors. Methods This is a phase 0, pilot prospective study taking place at a single center with 2 arms. In Arm A, patients are treated with pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle. Stereotactic body radiation therapy (SBRT) is delivered in 1-5 fractions starting on C1D15-28 and given every other day. In Arm B, patients who have started an immune checkpoint inhibitor within 60 days are treated with SBRT in addition to the current therapy. Results In this study we outline testing the feasibility of adding SBRT to pembrolizumab. Conclusion The ultimate goal of combination therapy is improved overall response, including tumors not treated with SBRT. This trial can be found registered online: NCT05488366. |
| first_indexed | 2024-04-25T02:13:37Z |
| format | Article |
| id | doaj.art-23421601d64348b5b1e00f854fbf53db |
| institution | Directory Open Access Journal |
| issn | 1526-2359 |
| language | English |
| last_indexed | 2024-04-25T02:13:37Z |
| publishDate | 2024-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-23421601d64348b5b1e00f854fbf53db2024-03-07T11:04:07ZengSAGE PublishingCancer Control1526-23592024-02-013110.1177/10732748241237331A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic SarcomaJeremy P. Harris MD, MPhilJino Park MDEric Ku MDSteven Seyedin MDRussell Stitzlein MDAmanda Goldin MDWen-Pin Chen MSChristine McLaren PhDAllen M. Chen MDWarren Chow MDObjectives Immunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the responses to immunotherapy is with stereotactic body radiation therapy (SBRT), which can enhance the antitumor CD8 T cell response through the release of tumor-specific antigens, potentially priming a more diverse class of T cell receptors. Methods This is a phase 0, pilot prospective study taking place at a single center with 2 arms. In Arm A, patients are treated with pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle. Stereotactic body radiation therapy (SBRT) is delivered in 1-5 fractions starting on C1D15-28 and given every other day. In Arm B, patients who have started an immune checkpoint inhibitor within 60 days are treated with SBRT in addition to the current therapy. Results In this study we outline testing the feasibility of adding SBRT to pembrolizumab. Conclusion The ultimate goal of combination therapy is improved overall response, including tumors not treated with SBRT. This trial can be found registered online: NCT05488366.https://doi.org/10.1177/10732748241237331 |
| spellingShingle | Jeremy P. Harris MD, MPhil Jino Park MD Eric Ku MD Steven Seyedin MD Russell Stitzlein MD Amanda Goldin MD Wen-Pin Chen MS Christine McLaren PhD Allen M. Chen MD Warren Chow MD A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma Cancer Control |
| title | A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma |
| title_full | A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma |
| title_fullStr | A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma |
| title_full_unstemmed | A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma |
| title_short | A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma |
| title_sort | pilot study of pembrolizumab combined with stereotactic ablative radiotherapy for patients with advanced or metastatic sarcoma |
| url | https://doi.org/10.1177/10732748241237331 |
| work_keys_str_mv | AT jeremypharrismdmphil apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT jinoparkmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT erickumd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT stevenseyedinmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT russellstitzleinmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT amandagoldinmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT wenpinchenms apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT christinemclarenphd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT allenmchenmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT warrenchowmd apilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT jeremypharrismdmphil pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT jinoparkmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT erickumd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT stevenseyedinmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT russellstitzleinmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT amandagoldinmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT wenpinchenms pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT christinemclarenphd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT allenmchenmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma AT warrenchowmd pilotstudyofpembrolizumabcombinedwithstereotacticablativeradiotherapyforpatientswithadvancedormetastaticsarcoma |